Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caner Saygin

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
Leukemia|December 28, 2023
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALLGeoffrey Parriott, Emma Hegermiller, Rosemary E Morman, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T lymphocyte acute lymphoblastic leukemiaGeoffrey Parriott, Emma Hegermiller, Rosemary E Morman, et al.
British Journal of Haematology|December 11, 2023
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitorsRafael Madero-Marroquin, Adam S DuVall, Caner Saygin, et al.
JCO Clinical Cancer Informatics|January 19, 2019
Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response RatesEhsan Malek, Caner Saygin, Rebecca Ye, et al.
Cancer Management and Research|December 8, 2021
Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution ExperienceAndrew Schaefer, Ying Huang, Adam Kittai, et al.
Blood Cancer Journal|March 4, 2021
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemiaBartholomew J Eisfelder, Caner Saygin, Joseph Wynne, et al.
Oncotarget|April 23, 2016
Cisplatin induces stemness in ovarian cancerAndrew Wiechert, Caner Saygin, Praveena S Thiagarajan, et al.
Ejhaem|January 27, 2025
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemiaRafael Madero-Marroquin, Ryan W Hunter, Caner Saygin, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 6, 2023
Sequential tumor molecular profiling identifies likely germline variantsIra L Kraft, Hatice Basdag, Ashwin Koppayi, et al.
Journal of Ovarian Research|November 19, 2019
Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancerElizabeth V Connor, Caner Saygin, Chad Braley, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
Leukemia|December 28, 2023
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALLGeoffrey Parriott, Emma Hegermiller, Rosemary E Morman, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T lymphocyte acute lymphoblastic leukemiaGeoffrey Parriott, Emma Hegermiller, Rosemary E Morman, et al.
British Journal of Haematology|December 11, 2023
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitorsRafael Madero-Marroquin, Adam S DuVall, Caner Saygin, et al.
JCO Clinical Cancer Informatics|January 19, 2019
Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response RatesEhsan Malek, Caner Saygin, Rebecca Ye, et al.
Cancer Management and Research|December 8, 2021
Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution ExperienceAndrew Schaefer, Ying Huang, Adam Kittai, et al.
Blood Cancer Journal|March 4, 2021
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemiaBartholomew J Eisfelder, Caner Saygin, Joseph Wynne, et al.
Oncotarget|April 23, 2016
Cisplatin induces stemness in ovarian cancerAndrew Wiechert, Caner Saygin, Praveena S Thiagarajan, et al.
Ejhaem|January 27, 2025
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemiaRafael Madero-Marroquin, Ryan W Hunter, Caner Saygin, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 6, 2023
Sequential tumor molecular profiling identifies likely germline variantsIra L Kraft, Hatice Basdag, Ashwin Koppayi, et al.
Journal of Ovarian Research|November 19, 2019
Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancerElizabeth V Connor, Caner Saygin, Chad Braley, et al.
Pageof 7